About Adaptive Biotechnologies
Adaptive Biotechnologies is a publicly listed company based in Seattle (United States) founded in 2009 by Harlan Robins and Chad Robins. Clinical diagnostics and drug discovery for immune diseases are provided. Adaptive Biotechnologies has raised $419.15 million across 18 funding rounds from investors including Microsoft, Illumina and LabCorp. The company has 619 employees. Adaptive Biotechnologies has completed 1 acquisition, including Sequenta. Its chief executive, as recorded, is Chad Robins. Its website adaptivebiotech.com draws about 64 thousand monthly visits. Adaptive Biotechnologies offers products and services including clonoSEQ, Adaptive Immunosequencing, and Pharma Services. Its focus areas include Life Sciences, Oncology, Drugs and Infectious Diseases. Its competitors include Moderna, Novavax and Generate Biomedicines; 2 of its 3 listed competitors have raised funding.
Company details
Adaptive Biotechnologies was founded in 2009 in Seattle, United States. Operations focus on the biotechnology sector, with services centered on immune disease diagnostics and drug discovery. The immunoSEQ sequencing technology is utilized to characterize the immune system, supporting scientific research and clinical development. clonoSEQ is employed for monitoring minimal residual disease in blood-based cancers. Cell therapies, vaccines, and antibody molecules are developed for infectious diseases.
- Headquarters Seattle, United States
- Employees 619
- Founders Harlan Robins, Chad Robins
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Phone•••• ••••
- Website adaptivebiotech.com
- Social LinkedIn X Facebook Instagram YouTube
- Legal Name Adaptive Biotechnologies Corporation
Products & Services of Adaptive Biotechnologies
Adaptive Biotechnologies offers a comprehensive portfolio of products and services, including clonoSEQ, Adaptive Immunosequencing, and Pharma Services.
NGS-based tool for assessing minimal residual disease in trials.
Technology for mapping immune receptors in drug discovery.
Services supporting clinical diagnostics and therapeutic development.
Apps and channels of Adaptive Biotechnologies
its YouTube channel Adaptive Biotechnologies has 677 subscribers.
Funding Insights of Adaptive Biotechnologies
Adaptive Biotechnologies has successfully raised a total of $419.15M across 18 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $419.15M
- Total Rounds 18
- First Round $4.55M
(Dec 2009)
- Investors Count 14
Latest 10 of 18 funding rounds of Adaptive Biotechnologies with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2018 | Series F | – | – | ||
| May 2015 | $195.1M | Series F | – | Matrix | |
| Jan 2015 | $94M | Series E | – | – | – |
| Aug 2014 | $115,430 | Grant | – | – | |
| Jul 2014 | $107M | Series D | – | – | |
| Jun 2014 | $244,699 | Grant | – | – | |
| Apr 2014 | $5M | Series C | – | Viking Global Investors | – |
| Sep 2013 | $2.5M | Grant | – | – | |
| Jul 2013 | $5.02M | Series B | – | – | – |
| Jun 2013 | $165,191 | Grant | – | – |
14 investors in total: 14 institutional.
Investors in Adaptive Biotechnologies
Adaptive Biotechnologies has secured backing from 14 investors, including institutional and venture fund investors. Prominent investors backing the company include Microsoft, Illumina and LabCorp.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Early-stage and late-stage biotech and finance companies are funded. | rockspringscapital.com | Baltimore, United States | ||
Private investment firm focused on multiple sectors | vikingglobal.com | Greenwich, United States | ||
Investing in Life Sciences sectors like Healthcare and Biotechnology. | casdincapital.com | |||
Early-stage ventures are funded by the investment firm. | matrix.vc | San Francisco, United States | ||
Private equity & fixed income investments focused hedge fund | senatorlp.com | New York, United States | ||
Venture and private equity investments are managed with global diversification. | tigerglobal.com | New York, United States | ||
Microsoft is recognized for software, hardware, and gaming solutions. | 1975 | microsoft.com | Redmond, United States | |
REIT that invests in campuses, multi-tenant spaces and build-to-suit facilities in the US | 1994 | are.com | Pasadena, United States | |
Research tools and instruments are manufactured for life sciences applications. | 1999 | bdbiosciences.com | Franklin Lakes, United States | |
Provider of laboratory tests for physicians | 1969 | labcorp.com | Burlington, United States |
Investor details for Adaptive Biotechnologies
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Adaptive Biotechnologies
305 people are tracked at Adaptive Biotechnologies (77 in leadership, 5 in board & advisors, 223 in team); the tracked headcount is 619.
| Name | Role | Group |
|---|---|---|
Harlan Robins | Co-Founder | Leadership |
Chad Robins | Co-Founder & CEO | Leadership |
Sharon Benzeno | Chief Commercial Officer, Immune Medicine | Leadership |
James Britt | Sr. Director, Field Operations & Commercial Data Management | Leadership |
Lisa Weatherholt | Vice President, Dx Customer Operations | Leadership |
Shalee Hawkins | Associate Director, Service Delivery & PPM | Leadership |
Kipp Akers | Director | Leadership |
Michael Dauer | Director, Molecular Laboratory Operations | Leadership |
Robin Toth | National Strategic Accounts Associate Director | Leadership |
Julie Rubinstein | President | Leadership |
Francis Lo | Chief People Officer | Leadership |
Srivatsa Venkatasubbarao | Director Of Development | Leadership |
Kayley Hall | Executive Assistant To Chief Executive Officer | Leadership |
Kirsten Wollam | Associate Director Of Operations | Leadership |
Ashley Derezes | Director, Financial Reporting | Leadership |
Brett Jensen | Southeast Region Senior Director, Adaptive Biotechnologies | Leadership |
Kyle Piskel | CFO | Leadership |
Jarrod Heck | Clinical Laboratory Director | Leadership |
Clarice McCauley | Chief Compliance Officer | Leadership |
Hugh Arnold | Vice President Of Clinical Lab Operations | Leadership |
285 more people are available in the full profile.
Complete people profiles for Adaptive Biotechnologies
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Adaptive Biotechnologies
Adaptive Biotechnologies is a publicly listed company on the NASDAQ with ticker symbol ADPT in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date05 Jul 2019
- Listed onFRA: 1HM
- Listed entityAdaptive Biotechnologies Corporation
- Exchange sectorHealth technology
- ISINUS00650F1093
- Share price$25.28 (-1.13% on the day) · 2026-10-13
- Market capitalisation$4.03B
- EPS (diluted, trailing year)$-0.41
- Volume (last session)1,954,784
Financials of Adaptive Biotechnologies
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $277.0M | -$59.5M | -$39.3M |
| 2024 | $179.0M | -$159.5M | -$134.1M |
| 2023 | $170.3M | -$225.2M | -$179.4M |
| 2022 | $185.3M | -$200.2M | -$170.0M |
| 2021 | $154.3M | -$207.3M | -$188.0M |
Detailed financial statements for Adaptive Biotechnologies
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Adaptive Biotechnologies
Adaptive Biotechnologies has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Sequenta.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Immuno-sequencing products are developed for disease diagnostics and treatment. | sequenta.com | San Francisco, United States | 2008 | Jan 2015 | •••• |
Complete acquisition details for Adaptive Biotechnologies
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Adaptive Biotechnologies
5 dated milestones of Adaptive Biotechnologies across 10 years, from founding to its latest funding, stage changes and deals.
- Founded Adaptive Biotechnologies is founded.
- Funding First funding round of $4.5M.
- Acquisition Acquires Sequenta.
- Funding Latest funding round, Series F,.
- IPO Lists on the stock exchange (IPO).
Competitors of Adaptive Biotechnologies
Adaptive Biotechnologies has 3 listed competitors in our database, 2 of them funded. They include Moderna, Novavax and Generate Biomedicines.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| novavax.com | 1987 | Gaithersburg, United States | 184 | Novel vaccines are developed using nanoparticle and matrix adjuvant technology. | ||
| generatebiomedicines.com | 2018 | Somerville, United States | $643M | 286 | Developer of novel protein-based therapeutics using machine learning and biological engineering |
Detailed competitors of Adaptive Biotechnologies
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Adaptive Biotechnologies
The website of Adaptive Biotechnologies (adaptivebiotech.com) receives about 63.9K visits a month and ranks #807,876 among all websites worldwide, #968 in Biotechnology and Pharmaceuticals.
- Monthly visits63.9K
▲ 60.1% vs previous month
- Unique visitors10.5K
per month
- Global rank#807,876
among all websites
- Category rank#968
Health · Biotechnology and Pharmaceuticals
- Bounce rate51%
- Pages per visit2.0
- Average visit1 min 26 sec
- DevicesDesktop 71% · Mobile 29%
Websites whose visitors overlap most with Adaptive Biotechnologies. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| shapetx.com | 100% | 2K | #11,569,347 | View details | |
| aerpio.com | 90% | View details | |||
| rarecyte.com | 84% | 3.2K | #5,681,690 | View details | |
| zymeworks.com | 82% | 32.9K | #989,344 | View details | |
| vrtx.com | 82% | 342.2K | #151,023 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 16 similar websites and full traffic analytics for Adaptive Biotechnologies
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 16 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Infectious Diseases
3 companies that operate in the same segment as Adaptive Biotechnologies (Infectious Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 | |
Therapeutics for drug-resistant bacterial infections are developed. | 2013 | Cambridge, Massachusetts, United States | USD 114.7 M | USD 59.62 M | 32 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Adaptive Biotechnologies
Complete news archive for Adaptive Biotechnologies
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Adaptive Biotechnologies
Adaptive Biotechnologies was founded in 2009.
Adaptive Biotechnologies is headquartered in Seattle, United States. It is registered at Seattle, Washington, United States.
Chad Robins is the CEO of Adaptive Biotechnologies, as recorded in our data. They have also founded this company.
Adaptive Biotechnologies is a funded company, having raised a total of $419.15M across 18 funding rounds to date. The company's 1st funding round was a Grant of $165.19K, raised on Dec 2009.
Adaptive Biotechnologies has 619 employees.
Annual revenue of Adaptive Biotechnologies is $276.98M as on Dec 31, 2025.
Adaptive Biotechnologies was founded in 2009 in Seattle, United States. Operations focus on the biotechnology sector, with services centered on immune disease diagnostics and drug discovery. The immunoSEQ sequencing technology is utilized to characterize the immune system, supporting scientific research and clinical development. clonoSEQ is employed for monitoring minimal residual disease in blood-based cancers. Cell therapies, vaccines, and antibody molecules are developed for infectious diseases.
Adaptive Biotechnologies's top competitors include Moderna, Generate Biomedicines and Novavax.
Adaptive Biotechnologies offers clonoSEQ, Adaptive Immunosequencing, and Pharma Services.
Yes, Adaptive Biotechnologies is publicly traded on NASDAQ under the ticker symbol ADPT.
Adaptive Biotechnologies has made 1 acquisition, including Sequenta.